<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931082</url>
  </required_header>
  <id_info>
    <org_study_id>AFCRO-136</org_study_id>
    <nct_id>NCT04931082</nct_id>
  </id_info>
  <brief_title>Probiotic Intervention for Stress and Cognition</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Parallel Clinical Trial of a Probiotic on Stress and Cognitive Function in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probi AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probi AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of probiotics on stress and cognitive function in healthy adults with moderate&#xD;
      stress&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine whether intake of probiotics reduce perceived stress</measure>
    <time_frame>12 weeks</time_frame>
    <description>Perceived stress will be evaluated with Cohen's Perceived Stress Scale (PSS) (min 0, max 40)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Stress</condition>
  <condition>Cognition</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule per day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in the study and comply with its procedures.&#xD;
&#xD;
          -  Be able to give written informed consent.&#xD;
&#xD;
          -  Be between 21 and 50 years.&#xD;
&#xD;
          -  Have moderate stress, as measured on Cohen's Perceived Stress Scale (PSS).&#xD;
&#xD;
          -  Are not suffering from depression or anxiety, confirmed by a Hospital Anxiety and&#xD;
             Depression Scale (HADS) score.&#xD;
&#xD;
          -  Are not regularly consuming probiotics for at least 4 weeks prior to the Screening&#xD;
             Visit.&#xD;
&#xD;
          -  Is in general good health, as determined by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of currently active irritable bowel syndrome (IBS), according to&#xD;
             Rome IV criteria.&#xD;
&#xD;
          -  Chronic intestinal disease, immunodeficiency disorder or immunosuppressive treatment.&#xD;
&#xD;
          -  Known gluten intolerance, lactose intolerance, milk protein allergy.&#xD;
&#xD;
          -  Intake of antibiotics within four weeks prior to the Screening Visit.&#xD;
&#xD;
          -  Hypersensitivity to any of the ingredients in the Investigational Product (IP).&#xD;
&#xD;
          -  Previous (within 5 years) or ongoing psychiatric illness.&#xD;
&#xD;
          -  Consumption of systemic psychotropics, rheumatoid drugs, steroid drugs or creams&#xD;
             containing cortisone.&#xD;
&#xD;
          -  Regular consumption of asthma medications.&#xD;
&#xD;
          -  History of any clinically significant disease or disorder which, in the opinion of the&#xD;
             Investigator, may either put the participant at risk if participating in the study, or&#xD;
             influence the results or the participantÂ´s ability to participate in the study.&#xD;
&#xD;
          -  Investigator considers the participant unlikely to comply with study procedures,&#xD;
             restrictions, and requirements.&#xD;
&#xD;
          -  Any disease, that by the investigator's judgement, could interfere with the intestinal&#xD;
             barrier function.&#xD;
&#xD;
          -  Participation in other clinical trials involving Investigational Product consumption&#xD;
             in the last month.&#xD;
&#xD;
          -  Desire and/or plans on changing current diet and/or exercise regime during the&#xD;
             participation of this trial.&#xD;
&#xD;
          -  Participants who are pregnant, breastfeeding, or wish to become pregnant during the&#xD;
             study.&#xD;
&#xD;
          -  Participants currently of childbearing potential, but not using an effective method of&#xD;
             contraception.&#xD;
&#xD;
          -  Have a malignant disease or any concomitant end-stage organ disease, which, in the&#xD;
             Investigator's judgment, contraindicates participation in the study.&#xD;
&#xD;
          -  Individuals who, in the opinion of the investigator, are considered to be poor&#xD;
             clinical attendees or unlikely for any reason to be able to comply with the trial.&#xD;
&#xD;
          -  Taking any supplements or vitamins notably known to affect cognitive function. Vitamin&#xD;
             D and calcium supplements permitted if on a stable dose for the previous 3 months.&#xD;
&#xD;
          -  History of heavy caffeinated beverage consumption (&gt;400 mg caffeine/day) within past 2&#xD;
             weeks prior to the Screening Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rebecca Kerin</last_name>
    <phone>+353 (0)21 430 7442</phone>
    <email>rkerin@atlantiatrials.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlantia Food Clinical Trials</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gut-brain axis</keyword>
  <keyword>Probiotics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

